On Tuesday, Avadel Pharmaceuticals (AVDL) stock received a positive adjustment to its Relative Strength (RS) Rating, from 76 to 82. ↑ X Massive Character Change Means...
AMSC Q1 Financial Highlights: Revenue Increased Over 33% Year Over Year to $40 Million Reported Expanded Gross Margin and Achieved Non-GAAP Net Income Generated $3.4 Million of Operating Cash Flow Company...
Vaxcyte, Inc. — VAX-31 Adult Phase 1/2 Study Topline Safety, Tolerability and Immunogenicity Data Expected in September 2024 — — Following VAX-31 Adult Phase 1/2 Study...